Cargando…

If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic

If it is correct that ineffective levels of transforming growth factors beta and their receptor account for old age being a risk factor for Alzheimer's disease (AD), then increasing TGFBR2 might be therapeutic. Pacltaxel is a direct way to increase TGFBR2 levels. Indirect ways that will increas...

Descripción completa

Detalles Bibliográficos
Autor principal:	Fessel, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202202/ https://www.ncbi.nlm.nih.gov/pubmed/32382652 http://dx.doi.org/10.1002/trc2.12019

Ejemplares similares

Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease
por: Fessel, Jeffrey
Publicado: (2019)

Caveolae, CD109, and endothelial cells as targets for treating Alzheimer's disease
por: Fessel, Jeffrey
Publicado: (2020)

Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types
por: Fessel, Jeffrey
Publicado: (2023)

Supplemental thiamine as a practical, potential way to prevent Alzheimer's disease from commencing
por: Fessel, Jeffrey
Publicado: (2021)

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
por: Fessel, Jeffrey
Publicado: (2022)

A vaccine to prevent initial loss of cognition and eventual Alzheimer's disease in elderly persons
por: Fessel, Jeffrey
Publicado: (2021)

Analysis of Why Alzheimer’s Dementia Never Spontaneously Reverses, Suggests the Basis for Curative Treatment
por: Fessel, Jeffrey
Publicado: (2023)

Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs
por: Fessel, Jeffrey
Publicado: (2019)

Intrathecal corticosteroids might slow Alzheimer’s disease progression
por: Alisky, Joseph Martin
Publicado: (2008)

How mind-body therapies might reduce pathological features of Alzheimer’s disease
por: Hüttenrauch, Melanie, et al.
Publicado: (2022)

The potential for one drug, administered at the earliest preclinical stage, to prevent the subsequent decline of cognition that eventuates in dementia
por: Fessel, Jeffrey
Publicado: (2020)

The paradox of opposite directions of gene expressions in MCI and AD suggests possible therapy to prevent progression of MCI to AD
por: Fessel, Jeffrey
Publicado: (2020)

Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence
por: Fessel, Jeffrey
Publicado: (2021)

Supplementary Pharmacotherapy for the Behavioral Abnormalities Caused by Stressors in Humans, Focused on Post-Traumatic Stress Disorder (PTSD)
por: Fessel, Jeffrey
Publicado: (2023)

Formulating treatment of major psychiatric disorders: algorithm targets the dominantly affected brain cell-types
por: Fessel, Jeffrey
Publicado: (2023)

Opioid-Related Harms: Simplistic Solutions to the Crisis Ineffective and Cause Collateral Damage
por: Gallagher, Romayne
Publicado: (2018)

Might Fibroblasts from Patients with Alzheimer’s Disease Reflect the Brain Pathology? A Focus on the Increased Phosphorylation of Amyloid Precursor Protein Tyr(682) Residue
por: Iannuzzi, Filomena, et al.
Publicado: (2021)

Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease
por: Waghabi, Mariana Caldas, et al.
Publicado: (2022)

Dementia in the oldest old: Beyond Alzheimer disease
por: Pierce, Aimee L., et al.
Publicado: (2017)

Resequencing of genes for transforming growth factor β1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy
por: McKnight, Amy Jayne, et al.
Publicado: (2007)

How Might Cocaine Interfere with Brain Development?
por: Hyman, Steven E
Publicado: (2008)

Promoter Hypomethylation of TGFBR3 as a Risk Factor of Alzheimer’s Disease: An Integrated Epigenomic-Transcriptomic Analysis
por: Song, Hui, et al.
Publicado: (2022)

Nurture might be nature: cautionary tales and proposed solutions
por: Hart, Sara A., et al.
Publicado: (2021)

TGFBR2 mediated phosphorylation of BUB1 at Ser-318 is required for transforming growth factor-β signaling
por: Nyati, Shyam, et al.
Publicado: (2020)

Next generation therapeutics for Alzheimer's disease
por: Bredesen, Dale E, et al.
Publicado: (2013)

Toward common mechanisms for risk factors in Alzheimer's syndrome
por: Medina, Miguel, et al.
Publicado: (2017)

Hypoxia in Alzheimer’s disease: effects of hypoxia inducible factors
por: Hassan, Halimatu, et al.
Publicado: (2020)

Transforming Growth Factor Beta Receptor 2 (TGFBR2) Promoter Region Polymorphisms May Be Involved in Mandibular Retrognathism
por: Kirschneck, Margarita, et al.
Publicado: (2022)

On the Origins of a Species: What Might Explain the Rise of Candida auris?
por: Jackson, Brendan R., et al.
Publicado: (2019)

Augmentation of transforming growth factor-β signaling for the treatment of neurological disorders
por: Luo, Jian
Publicado: (2023)

Detrimental and synergistic role of epilepsy – Alzheimer’s disease risk factors
por: Filippov, Mikhail A., et al.
Publicado: (2019)

Increased intron retention is linked to Alzheimer’s disease
por: Ong, Chin-Tong, et al.
Publicado: (2019)

Coping with COVID-19 in Sub-Saharan Africa: What Might the Future Hold?
por: Mennechet, Franck J. D., et al.
Publicado: (2020)

Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
por: Weninger, Stacie, et al.
Publicado: (2020)

Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease
por: Monteiro, Kadja Luana Chagas, et al.
Publicado: (2020)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Glial-derived transforming growth factor β1 (TGF-β1): a key factor in multiple sclerosis neuroinflammation
por: Guevara, Coram, et al.
Publicado: (2020)

On the horizon—the value and promise of the global pipeline of Alzheimer's disease therapeutics
por: Cole, Michael A., et al.
Publicado: (2020)

Estrogens still represent an attractive therapeutic approach for Alzheimer’s disease
por: Tamagno, Elena, et al.
Publicado: (2021)

Diagnostic and therapeutic potential of exosomal miRNAs in Alzheimer’s disease
por: Manna, Ida, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6a9i3rb1n31jvpe7vua2ekdtv6